Subtype
Thyroid Gland Anaplastic Carcinoma
CI-CAN-00004121ATCExplore in graph →
22 active trials2 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004121ATCExplore in graph →
Clinical trials
61 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | terminated | Phase 2 | 34 | Eisai Inc.INDUSTRY | 5 | Oct 15, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer |
| terminated |
| Phase 2 |
| 20 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jan 19, 2018 |
| clinicaltrials |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2017 | clinicaltrials |
| NCT02516774 | A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers(TAM-RT) | withdrawn | Phase 1 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer(FACT) | terminated | Phase 2 / Phase 3 | 80 | Mateon TherapeuticsINDUSTRY | 12 | Jun 9, 2014 | clinicaltrials |
| NCT01701349 | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer(FACT2) | withdrawn | Phase 3 | 0 | Mateon TherapeuticsINDUSTRY | 0 | May 1, 2014 | clinicaltrials |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2014 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00068497 | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | completed | N/A | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00280852 | Review of Multimodality Management of Anaplastic Thyroid Cancer | completed | — | 5 | Alberta Health servicesOTHER | 1 | Nov 21, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Oct 15, 2019source: clinicaltrials